BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24777276)

  • 1. Risk of relapse phenotype recurrence in multiple sclerosis.
    Kalincik T; Buzzard K; Jokubaitis V; Trojano M; Duquette P; Izquierdo G; Girard M; Lugaresi A; Grammond P; Grand'Maison F; Oreja-Guevara C; Boz C; Hupperts R; Petersen T; Giuliani G; Iuliano G; Lechner-Scott J; Barnett M; Bergamaschi R; Van Pesch V; Amato MP; van Munster E; Fernandez-Bolanos R; Verheul F; Fiol M; Cristiano E; Slee M; Rio ME; Spitaleri D; Alroughani R; Gray O; Saladino ML; Flechter S; Herbert J; Cabrera-Gomez JA; Vella N; Paine M; Shaw C; Moore F; Vucic S; Savino A; Singhal B; Petkovska-Boskova T; Parratt J; Sirbu CA; Rozsa C; Liew D; Butzkueven H;
    Mult Scler; 2014 Oct; 20(11):1511-22. PubMed ID: 24777276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants.
    Vercellino M; Romagnolo A; Mattioda A; Masera S; Piacentino C; Merola A; Chiò A; Mutani R; Cavalla P
    Acta Neurol Scand; 2009 Feb; 119(2):126-30. PubMed ID: 18684216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of different relapse phenotypes to disability in multiple sclerosis.
    Stewart T; Spelman T; Havrdova E; Horakova D; Trojano M; Izquierdo G; Duquette P; Girard M; Prat A; Lugaresi A; Grand'Maison F; Grammond P; Sola P; Shaygannejad V; Hupperts R; Alroughani R; Oreja-Guevara C; Pucci E; Boz C; Lechner-Scott J; Bergamaschi R; Van Pesch V; Iuliano G; Ramo C; Taylor B; Slee M; Spitaleri D; Granella F; Verheul F; McCombe P; Hodgkinson S; Amato MP; Vucic S; Gray O; Cristiano E; Barnett M; Sanchez Menoyo JL; van Munster E; Saladino ML; Olascoaga J; Prevost J; Deri N; Shaw C; Singhal B; Moore F; Rozsa C; Shuey N; Skibina O; Kister I; Petkovska-Boskova T; Ampapa R; Kermode A; Butzkueven H; Jokubaitis V; Kalincik T;
    Mult Scler; 2017 Feb; 23(2):266-276. PubMed ID: 27055805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.
    Kalincik T; Vivek V; Jokubaitis V; Lechner-Scott J; Trojano M; Izquierdo G; Lugaresi A; Grand'maison F; Hupperts R; Oreja-Guevara C; Bergamaschi R; Iuliano G; Alroughani R; Van Pesch V; Amato MP; Slee M; Verheul F; Fernandez-Bolanos R; Fiol M; Spitaleri DL; Cristiano E; Gray O; Cabrera-Gomez JA; Shaygannejad V; Herbert J; Vucic S; Needham M; Petkovska-Boskova T; Sirbu CA; Duquette P; Girard M; Grammond P; Boz C; Giuliani G; Rio ME; Barnett M; Flechter S; Moore F; Singhal B; Bacile EA; Saladino ML; Shaw C; Skromne E; Poehlau D; Vella N; Spelman T; Liew D; Kilpatrick TJ; Butzkueven H;
    Brain; 2013 Dec; 136(Pt 12):3609-17. PubMed ID: 24142147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I; Coret F; Valero C; Pascual AM; Magraner MJ; Landete L; Casanova B
    Mult Scler; 2008 Jun; 14(5):636-9. PubMed ID: 18566027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural history of relapses in multiple sclerosis.
    Vollmer T
    J Neurol Sci; 2007 May; 256 Suppl 1():S5-13. PubMed ID: 17346747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disability and prognosis of relapsing remitting multiple sclerosis, is it different in Iraqi patients?
    Hasan ZN
    Neurosciences (Riyadh); 2011 Jul; 16(3):233-6. PubMed ID: 21677613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of relapse rate in MS clinical trials.
    Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
    Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
    Novotna M; Paz Soldán MM; Abou Zeid N; Kale N; Tutuncu M; Crusan DJ; Atkinson EJ; Siva A; Keegan BM; Pirko I; Pittock SJ; Lucchinetti CF; Noseworthy JH; Weinshenker BG; Rodriguez M; Kantarci OH
    Neurology; 2015 Aug; 85(8):722-9. PubMed ID: 26208962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific clinical phenotypes in relapsing multiple sclerosis: The impact of relapses on long-term outcomes.
    Scott TF; Gettings EJ; Hackett CT; Schramke CJ
    Mult Scler Relat Disord; 2016 Jan; 5():1-6. PubMed ID: 26856936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic indicators for long-term disability in multiple sclerosis patients.
    Damasceno A; Von Glehn F; Brandão CO; Damasceno BP; Cendes F
    J Neurol Sci; 2013 Jan; 324(1-2):29-33. PubMed ID: 23073568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does pregnancy alter the long-term course of multiple sclerosis?
    Karp I; Manganas A; Sylvestre MP; Ho A; Roger E; Duquette P
    Ann Epidemiol; 2014 Jul; 24(7):504-8.e2. PubMed ID: 24935463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A composite score to predict short-term disease activity in patients with relapsing-remitting MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2007 Sep; 69(12):1230-5. PubMed ID: 17875911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study.
    Leone MA; Bonissoni S; Collimedaglia L; Tesser F; Calzoni S; Stecco A; Naldi P; Monaco F
    Mult Scler; 2008 May; 14(4):485-93. PubMed ID: 18208889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incomplete nature of multiple sclerosis relapse resolution.
    Lublin FD
    J Neurol Sci; 2007 May; 256 Suppl 1():S14-8. PubMed ID: 17337274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.
    Kalincik T; Manouchehrinia A; Sobisek L; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Girard M; Prat A; Duquette P; Grammond P; Sola P; Hupperts R; Grand'Maison F; Pucci E; Boz C; Alroughani R; Van Pesch V; Lechner-Scott J; Terzi M; Bergamaschi R; Iuliano G; Granella F; Spitaleri D; Shaygannejad V; Oreja-Guevara C; Slee M; Ampapa R; Verheul F; McCombe P; Olascoaga J; Amato MP; Vucic S; Hodgkinson S; Ramo-Tello C; Flechter S; Cristiano E; Rozsa C; Moore F; Luis Sanchez-Menoyo J; Laura Saladino M; Barnett M; Hillert J; Butzkueven H;
    Brain; 2017 Sep; 140(9):2426-2443. PubMed ID: 29050389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.
    Lage MJ; Carroll CA; Fairman KA
    J Med Econ; 2013 Sep; 16(9):1146-53. PubMed ID: 23844620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Sclerosis Relapses: Epidemiology, Outcomes and Management. A Systematic Review.
    Kalincik T
    Neuroepidemiology; 2015; 44(4):199-214. PubMed ID: 25997994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.